Paragraph IV Disputes

Announcing ACI’s

Hatch-Waxman Advisory Board

Patents covering critical pharmaceutical products worth more than $30 billion annually are on the precipice of expiration.

Conquer the litigation challenges that this patent onslaught will bring for brand name and generics in the Paragraph IV arena.

Here’s what previous years’ delegates had to say:

“Speakers & Materials were Superior” – VP Regulatory Counsel, Alvogen
“Excellent & Informative” – Head Patent Cell, Alembic Ltd, INDIA

American Conference Institute’s 6th Annual Paragraph IV Disputes conference is the undisputed source for Hatch-Waxman litigation strategies for brand-names and generics. This event — which is widely recognized for setting the standards for Paragraph IV litigation and which also serves as the annual meeting place for the “who’s who” of pharmaceutical patent litigation — is now the single forum on which brand name and generic companies can rely for answers during this turbulent time in which the balance of power designed by the Hatch-Waxman Act may completely unravel. Come to this conference and get the up-to-the minute information that you need to prepare for the new litigation confrontations to come.

Brand name pharmaceutical companies are moving closer than ever to the edge of the patent cliff. However, generic manufacturers are facing their own hurdles as fewer opportunities for 180-day exclusivity will remain.

The industry has reached the long dreaded patent cliff of 2011. Brand name manufacturers are struggling to fill a drying pipeline and extend patent life through other statutory and regulatory conventions. Meanwhile, generics eye the ultimate Hatch-Waxman prize of 180-day exclusivity— knowing that such opportunities in the future may be short-lived as there will be few patented drug products worth coveting. These factors have turned Paragraph IV litigation into a no-holds barred fight and have raised the monetary ante to an unprecedented level.

New legislative developments, evolving case law and mounting enforcement actions are increasing this anxiety.

Moreover, the passage of biosimilars legislation, the passage of the America Invents Act and the never ending controversy surrounding reverse payment settlements have only added to the complexities surrounding this litigation. In this chaotic environment one thing is clear: it is more imperative than ever before for brand-name and generic drug manufacturers to have the offensive moves and defensive plays that they need to meet the evolving challenges of pharmaceutical patent endgame litigation.

Turn your IP uncertainties into opportunities.

In this high stakes and ruthless endgame, not a moment can be lost. Featuring preeminent patent litigators and in-house industry experts from both branded and generic companies, along with representatives from the FTC and preeminent judges, you cannot afford to miss this event. 

Don’t delay - this conference does sell out - ensure your seat by reserving your spot now! Register by calling 888-224-2480, emailing CustomerService@AmericanConference.com  or registering online at www.AmericanConference.com/PIVDisputesNYC.  

Full conference details are on the way shortly. If you are interested in speaking at this event, contact Lisa Piccolo at L.Piccolo@americanconference.com. For information on sponsoring or exhibiting at this event, contact Esther Fleischhacker at e.fleischhacker@americanconference.com.

Supporting Sponsors:

Cocktail Reception Host:

Luncheon Sponsor:

Associate Sponsor:

VIP Breakfast Sponsor:

Executive Sponsor:

Sponsored by:

- Actions -

- Share -